Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase‐2 inhibitors

Matrix metalloproteinase‐2 (MMP‐2) is a potential target in metastases. Regression (conventional 2D QSAR) and classification (recursive partitioning (RP), Bayesian modelling) QSAR, pharmacophore mapping and 3D QSAR (comparative molecular field analysis and comparative molecular similarity analysis) were performed on 202 MMP‐2 inhibitors.

[1]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[2]  C. Sheehan,et al.  Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  David E. Shaw,et al.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..

[4]  Wenfang Xu,et al.  Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part I). , 2009, Bioorganic & medicinal chemistry.

[5]  T. Jha,et al.  QSAR for analogs of 1,5-N,N'-disubstituted-2-(substituted benzenesulphonyl) glutamamides as antitumor agents , 2007 .

[6]  Wenfang Xu,et al.  Design, synthesis, and evaluation of novel galloyl pyrrolidine derivatives as potential anti-tumor agents. , 2006, Bioorganic & medicinal chemistry.

[7]  BioChem Press,et al.  Pharmacophore Mapping of Tricyclic Isoxazoles for Their Affinity Towards Alpha-2 Adrenoreceptors # , 2006 .

[8]  H. Fang,et al.  Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. , 2008, Bioorganic & medicinal chemistry.

[9]  Jian Zhang,et al.  Novel matrix metalloproteinase inhibitors derived from quinoxalinone scaffold (Part I). , 2010, Bioorganic & medicinal chemistry.

[10]  R. Cramer,et al.  Recent advances in comparative molecular field analysis (CoMFA). , 1989, Progress in clinical and biological research.

[11]  C. Hansch,et al.  Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. , 2007, Bioorganic & medicinal chemistry.

[12]  S P Gupta,et al.  A quantitative structure-activity relationship study on some matrix metalloproteinase and collagenase inhibitors. , 2003, Bioorganic & medicinal chemistry.

[13]  Wenfang Xu,et al.  Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part II). , 2009, Bioorganic & medicinal chemistry.

[14]  S. Zucker,et al.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment , 2000, Oncogene.

[15]  Hiroyuki Yamamoto,et al.  Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer Invasion, Apoptosis, Growth, and Angiogenesis , 2006, Experimental biology and medicine.

[16]  A Comparative QSAR Study on Carbonic Anhydrase and Matrix Metalloproteinase Inhibition by Sulfonylated Amino Acid Hydroxamates , 2003, Journal of enzyme inhibition and medicinal chemistry.

[17]  Li Zhang,et al.  Design, synthesis and preliminary evaluation of new cinnamoyl pyrrolidine derivatives as potent gelatinase inhibitors. , 2006, Bioorganic & medicinal chemistry.

[18]  S. Mobashery,et al.  Recent advances in MMP inhibitor design , 2006, Cancer and Metastasis Reviews.

[19]  BioChem Press,et al.  Search for Structural Requirements of 2-Phenylimidazo(1,2-. ) pyridineacetamide Analogs to Improve Affinity and Selectivity towards Central and/or Peripheral Benzodiazepine Receptors , 2007 .

[20]  Lei Zhang,et al.  Design, Synthesis, and Preliminary Activity Evaluation of Novel Peptidomimetics as Aminopeptidase N/CD13 Inhibitors , 2011, Archiv der Pharmazie.

[21]  MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3. , 2003, Bioorganic & medicinal chemistry letters.

[22]  P. Jurs,et al.  Development and use of charged partial surface area structural descriptors in computer-assisted quantitative structure-property relationship studies , 1990 .

[23]  F. Mannello,et al.  Matrix metalloproteinase inhibitors as anticancer therapeutics. , 2005, Current cancer drug targets.

[24]  Philip Prathipati,et al.  Global Bayesian Models for the Prioritization of Antitubercular Agents , 2008, J. Chem. Inf. Model..

[25]  D. Hadjipavlou-Litina,et al.  Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. , 2005, Current medicinal chemistry.

[26]  Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives. , 2003, Bioorganic & medicinal chemistry letters.

[27]  Wenfang Xu,et al.  Design, synthesis, and activity of caffeoyl pyrrolidine derivatives as potential gelatinase inhibitors. , 2004, Bioorganic & medicinal chemistry.

[28]  Anton J. Hopfinger,et al.  Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships , 1994, J. Chem. Inf. Comput. Sci..

[29]  A quantitative structure–activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from funtionalized 4-aminoprolines , 2003 .

[30]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[31]  Hans Matter,et al.  Recent advances in the design of matrix metalloprotease inhibitors. , 2004, Current opinion in drug discovery & development.

[32]  A. Ghose,et al.  Atomic Physicochemical Parameters for Three‐Dimensional Structure‐Directed Quantitative Structure‐Activity Relationships I. Partition Coefficients as a Measure of Hydrophobicity , 1986 .

[33]  P. Roy,et al.  Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques. , 2009, European journal of medicinal chemistry.

[34]  R. Kizek,et al.  Matrix metalloproteinases. , 2010, Current medicinal chemistry.

[35]  Hedvig Tordai,et al.  Hydroxamate-based peptide inhibitors of matrix metalloprotease 2. , 2005, Biochimie.

[36]  P. Bai,et al.  MATRIX METALLO PROTEINASES IN CARCINOMA OF CERVIX - A REVIEW , 2011 .

[37]  Rainer Franke,et al.  Theoretical drug design methods , 1984 .

[38]  Kunal Roy,et al.  Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives. , 2009, European journal of medicinal chemistry.

[39]  Anthony E. Klon,et al.  Improved Naïve Bayesian Modeling of Numerical Data for Absorption, Distribution, Metabolism and Excretion (ADME) Property Prediction , 2006, J. Chem. Inf. Model..

[40]  J. Pin,et al.  Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. , 2005, Journal of medicinal chemistry.

[41]  BioChem Press,et al.  Predictive Comparative QSAR Modeling of 4-Pyridones as Potent Antimalarials , 2010 .

[42]  Harshinder Singh,et al.  Application of the Random Forest Method in Studies of Local Lymph Node Assay Based Skin Sensitization Data , 2005, J. Chem. Inf. Model..

[43]  H. Fang,et al.  Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors. , 2008, European journal of medicinal chemistry.

[44]  K. Roy,et al.  Chemometric modeling, docking and in silico design of triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors as antimalarials. , 2010, European journal of medicinal chemistry.

[45]  Asim Kumar Debnath,et al.  Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. , 2002, Journal of medicinal chemistry.